Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Active, not recruitingOBSERVATIONAL
Enrollment

2,600

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)

First-time treatment with Metformin Hydrochloride and Empagliflozin Tablets (metformin 500mg and empagliflozin 5mg per table) for at least 6 months

Trial Locations (1)

Unknown

Endocrinology Department, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Liaoning Health Industry Group Fushun Mining General Hospital

UNKNOWN

collaborator

Liaoning Health Industry Group Benxi Steel General Hospital

UNKNOWN

collaborator

Changsha Fourth Hospital

OTHER_GOV

collaborator

Second Hospital of Shanxi Medical University

OTHER

collaborator

The First People's Hospital of Kunshan

OTHER

collaborator

Suzhou Ninth People's Hospital

UNKNOWN

collaborator

the First Affiliated Hospital of Anhui University of Science and Technology

UNKNOWN

collaborator

Mingguang People's Hospital

UNKNOWN

collaborator

the People's Hospital Longhua Shenzhen

UNKNOWN

collaborator

Affiliated Hospital of North Sichuan Medical College

OTHER

collaborator

Yiyang County People's Hospital

UNKNOWN

collaborator

THE SECOND PEOPLE'S HOSPITAL, WUHU

UNKNOWN

collaborator

The First People's Hospital of Zhangjiagang

UNKNOWN

collaborator

Yixing People's Hospital

OTHER

collaborator

Shijiazhuang People's Hospital

OTHER

collaborator

Guiyang First People's Hospital

UNKNOWN

collaborator

Lanzhou University Second Hospital

OTHER

collaborator

Tiefa Coal Industry Group General Hospital

UNKNOWN

collaborator

Southern Medical University Shenzhen Hospital

UNKNOWN

collaborator

The Second Hospital of Shijiazhuang

UNKNOWN

collaborator

Ningbo University Affiliated People's Hospital

UNKNOWN

collaborator

Dongyang People's Hospital

OTHER

collaborator

Xiangyang Central Hospital

OTHER

collaborator

Li Hui Li Hospital

UNKNOWN

collaborator

Nanning Second People's Hospital

OTHER

collaborator

Hunan Provincial People's Hospital Ma Wang Dui Branch

UNKNOWN

collaborator

The Second Affiliated Hospital of Bengbu Medical College

UNKNOWN

collaborator

Ruyang County People's Hospital

UNKNOWN

collaborator

Kaifeng People's Hospital

UNKNOWN

collaborator

Dingzhou People's Hospital

UNKNOWN

collaborator

The Second People's Hospital of Changshu

UNKNOWN

collaborator

The Second Affiliated Hospital of Henan University of Science and Technology

UNKNOWN

collaborator

Dengzhou People's Hospital

UNKNOWN

collaborator

Taizhou First People's Hospital

OTHER

collaborator

Red Cross Hospital, Hangzhou, China

OTHER

collaborator

The First People's Hospital of Lin'an District

UNKNOWN

collaborator

China Resources Wugang General Hospital

UNKNOWN

collaborator

Yiwu Central Hospital

OTHER

collaborator

The First People's Hospital of Jiashan County

UNKNOWN

collaborator

The First People's Hospital of Tongxiang City

UNKNOWN

collaborator

Shaoxing Central Hospital

OTHER

collaborator

The First People's Hospital of Jiande City

UNKNOWN

collaborator

Beilun District People's Hospital

UNKNOWN

collaborator

Huantai County People's Hospital

UNKNOWN

collaborator

Fifth Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University

OTHER

collaborator

The Affiliated Hospital of Shaanxi University of Chinese Medicine

UNKNOWN

collaborator

Zhangjiagang Traditional Chinese Medicine Hospital

UNKNOWN

lead

Sun Yat-sen University

OTHER

NCT07003191 - Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes | Biotech Hunter | Biotech Hunter